StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Stock analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of BLPH stock opened at $0.06 on Friday. The company has a market cap of $672,650.00, a price-to-earnings ratio of -0.07 and a beta of 0.67. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $11.48. The firm has a 50 day moving average of $0.06 and a 200-day moving average of $0.08.

Institutional Trading of Bellerophon Therapeutics

Several large investors have recently modified their holdings of BLPH. Perceptive Advisors LLC acquired a new stake in shares of Bellerophon Therapeutics during the 1st quarter worth approximately $7,338,000. BlackRock Inc. grew its position in shares of Bellerophon Therapeutics by 34.8% during the 2nd quarter. BlackRock Inc. now owns 129,876 shares of the biotechnology company’s stock worth $90,000 after buying an additional 33,527 shares during the period. Geode Capital Management LLC grew its position in shares of Bellerophon Therapeutics by 49.0% during the 1st quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock worth $755,000 after buying an additional 31,460 shares during the period. HRT Financial LP acquired a new stake in shares of Bellerophon Therapeutics during the 4th quarter worth approximately $25,000. Finally, Renaissance Technologies LLC grew its position in shares of Bellerophon Therapeutics by 13.0% during the 2nd quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock worth $258,000 after buying an additional 24,100 shares during the period. Institutional investors and hedge funds own 10.61% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.